



Cyient DLM Ltd

Q2FY25

Cyient DLM Ltd.


CMP*	Target	Potential Upside	Market Cap (INR Mn)	Recommendation	Sector
INR 661	INR 842	27.4%	INR 52,814	BUY	Electronic-Component

Result Highlights of Q1FY25:

- Cyient DLM reported 33%/34% YoY growth in revenue/EBITDA during Q2FY25 on account of 82% growth in defense & 20% growth in aerospace. Despite seeing a beat on topline, PAT in Q2FY25 came lower than expected due to higher interest cost.
- Q2FY25 witnessed higher proportion of execution for a large domestic company in defence segment which led to higher domestic mix as opposed to normal quarters. Though EBITDA margin expanded to 8.1% but higher domestic mix impacted the margins.
- The PAT for the quarter recorded a growth of 5.5% on YoY basis during the quarter, lower than the EBITDA growth of 34%. The PAT growth number trailed the EBITDA growth due to higher interest cost on account of increased debt.
- The order book for the company was recorded at INR 19,790 Mn for the quarter and the order book is expected to turn better in the coming quarters given more than \$500 Mn weighted order pipeline.
- We believe the margin is on an improving trajectory and meaningful expansion should be reflected in FY26E while in FY25E the margins should be in double digit/ close to double digit. **Consequently, we have slightly revised our FY26E earnings estimates by -3.5% to INR 19 (Previous INR 20) and maintain our BUY rating on the stock with target price of INR 842 (27.4% upside), valued at a PE of 45x FY26E EPS.**

MARKET DATA

Shares outs (Mn)	79.3
Equity Cap (INR Mn)	9,090
Mkt Cap (INR Mn)	52,814
52 Wk H/L (INR)	884/581
Volume Avg (3m K)	369
Face Value (INR)	10
Bloomberg Code	Cyient DLM IN

SHARE PRICE PERFORMANCE**MARKET INFO**

SENSEX	80,221
NIFTY	24,482

KEY FINANCIALS

INR Millions	FY23	FY24	FY25E	FY26E	FY27E
Revenue	8,320	11,919	15,336	20,251	26,742
EBITDA	878	1,110	1,569	2,381	3,266
EBITDA margin (%)	11%	9%	10%	12%	12%
PAT	317	612	954	1,498	2,105
PAT margin (%)	4%	5%	6%	7%	8%
EPS	4	8	12	19	27
P/E (x)	165x	86x	55x	35x	25x

Source: Company, KRChoksey Research

Defense & Aerospace Segment Driving the Growth but Interest Cost Impacted the PAT

- The defense segment recorded a growth of 82% on YOY basis on account of ramp-up in execution for one of the large clients in India. The aerospace segment also delivered a growth of 20% on YoY basis.
- Despite delivering 32%/ 34% Gross Profit/ EBITDA growth (YoY basis) during the quarter, the PAT growth moderated to mid single digit largely on account of increase in interest cost (+37% YoY) and moderation in other income (-20% YoY).
- However, the short-term debt should come down in H2 as the free-cash flow turns positive during the second half of the year. The net working capital days also reduced to 127 days in Q2 and it should improve to 90-100 days in the coming quarters.
- Strong Order Pipeline and Order Book Should Strengthen in H2**
- The order pipeline remains strong for H2 and the order book stood at 19,790 Mn during Q2FY25.
- It won new logo from premier defense PSU in India, specializing in missile systems and allied defense equipment. The second one was from global oilfield service company.
- The recent acquisition should also help in grabbing multiple fortune 500 clients through in Industrial and medical.

SHARE HOLDING PATTERN (%)

Particulars (%)	Sep-24	June-24	Mar-24
Promoters	52.2	66.7	66.7
DILs	27.8	17.4	7.0
FILs	7.7	5.1	12.6
Others	12.3	10.8	13.7
Total	100.0	100.0	100.0

*Based on Today's closing

30%

56%

Revenue CAGR between FY24 and FY26E

Adj. PAT CAGR between FY24 and FY26E

Cyient DLM Ltd.

Key Concall Highlights:

- The acquisition of Altek Electronics is expected to strengthen Cyient DLM's position in the Industrial and Medical segments. Altek Electronics has 96% exposure in these segments, with strong capabilities in precision, quality control, and advanced inspection methods, including automated testing and assembly services.
- Altek Electronics operates with double-digit EBITDA margins, aligning well with Cyient DLM's organic EBITDA margin levels. Additionally, Cyient DLM will leverage Altek Electronics' ITAR certification to expand into the U.S. defense sector. The closer proximity to U.S. clients is expected to help the company tap into the U.S. defense market. Furthermore, Altek Electronics will enhance Cyient DLM's build-to-spec (B2S) capabilities.
- On the acquisition front, most of Altek's assets are tangible, meaning there should be no significant impact from goodwill amortization.
- The order book has been declining for several quarters, standing at INR 19,790 million in Q2FY25. However, management is confident that the strong order pipeline will convert into confirmed orders by the second half of FY25.
- The geopolitical situation in Israel has also affected the supply chain during the quarter, though the company managed the situation effectively. The impact was not cost-related, but component scheduling has been increasingly delayed, which presents a risk in the coming quarters. The Israel operations contribute approximately 20 days to the overall working capital cycle, with net working capital days in Q2FY25 standing at 127.
- In terms of focus, Cyient DLM is looking to expand into new geographies and sectors, while continuing to emphasize its existing areas of operation. The company is also exploring opportunities in the electric vehicle (EV) space, and we believe that the automotive sector will be a key area of focus in the coming years. Expansion into this segment is expected to be ROCE-accretive, as working capital days are more favorable in the automotive industry.
- The management also clarified that the resignation of the head of sales was due to medical reasons.
- Regarding margins, the company stated that FY26E margins are expected to improve significantly, as the large domestic order with lower margins is concluding. The rest of the business operates with very healthy margins, which should lead to a notable margin improvement.


Valuation and view:

Cyient DLM delivered strong performance in terms of topline and operating profit, but its bottom-line growth was hindered by higher interest costs. However, the second half of FY25 is expected to perform better than the first half. The recent acquisition of Altek Electronics is projected to start contributing to revenue from Q3FY25 onwards and should positively impact EBITDA margins. Management has guided that margins in the second half will be significantly improved, approaching double-digit levels, as the company completes a large domestic order with lower margins. This healthier margin mix, combined with strong growth in the aerospace and defense sectors, is expected to drive robust growth in both topline and bottom line. Following the Q2FY25 conference call, we have slightly revised our earnings estimates, expecting major margin expansion in FY26, with FY25 margins hovering near double digits. As a result, we have revised our FY26E earnings estimate slightly downwards by 3.5%. **We project the company to achieve a revenue/PAT CAGR of 30%/56% during FY24-FY26E. We maintain our "BUY" rating on the stock, valuing it at a P/E multiple of 45x on FY26E EPS of INR 19 (previously INR 20), resulting in a target price of INR 842 (27.4% upside) per share.**


Cyient DLM Ltd.**Q2 FY25 Result:**

Particulars (INR Mn)	Q2FY24	Q1FY25	Q2FY25	Q-o-Q	Y-o-Y	H1FY24	H1FY25	YoY
Revenue From Operations	2,918	2,579	3,895	51%	33%	5,090	6,473	27%
COGS	2312	1927	3092	60%	34%	3,940	5,019	
COGS% of revenue	79%	75%	78%			77%	78%	
Gross Profit	607	652	802	23%	32%	1,150	1,454	26%
Gross Margin (%)	20.7%	25.3%	20.6%	-467	-18 bps	23%	22%	
Employee Expenses	267	328	336	2%	26%	511	664	
Other Expenses	104	124	150	21%	44%	204	274	
EBITDA	235	200	316	58%	34%	435	516	19%
EBITDA Margin %	8.1%	7.8%	8.1%	37 bps	6 bps	8.6%	7.9%	
Other Income	93	89	71	-20%	-24%	102	160	
Depreciation	55	67	69	3%	25%	103	136	
Finance Cost	76	80	110	37%	45%	167	190	
Profit Before Tax	198	142	209	47.5%	5.7%	268	351	31%
Tax								
Total Tax	51	36	54	53%	6%	68	90	
Tax %	26%	25%	26%			25%	26%	
Profit After Tax	147	106	155	46%	5%	200	261	30%
PAT Margin %	5.0%	4.1%	3.9%	-14 bps	-105 bps	3.9%	4.0%	

Source: Company, KRChoksey Research

Revenue (INR Mn)

Source: Company, KRChoksey Research

EBITDA (INR Mn)

Source: Company, KRChoksey Research

Cyient DLM Ltd.**KEY FINANCIALS****Exhibit 1: Profit & Loss Statement**

Particulars (INR Million)	FY23	FY24	FY25E	FY26E	FY27E
Revenue From Operations	8,320	11,919	15,336	20,251	26,742
Other income	63	278	280	124	96
Total Revenue	8,383	12,197	15,616	20,375	26,838
COGS	6,452	9,200	11,797	15,398	20,283
Gross Profit	1,868	2,719	3,539	4,853	6,459
Gross Profit Margin%	22.5%	22.8%	23.1%	24.0%	24.2%
Employee Benefit Expenses	647	1,174	1,390	1,663	2,167
Other expenses	343	435	580	810	1,027
Operating Expenses	7,443	10,809	13,768	17,870	23,476
EBITDA Profit	878	1,110	1,569	2,381	3,266
EBITDA %	10.6%	9.3%	10.2%	11.8%	12.2%
Finance Cost	315	344	303	179	191
Depreciation	194	223	263	315	345
Total Expenses	7,952	11,376	14,334	18,364	24,012
Profit Before Taxes	432	821	1,282	2,011	2,826
Total Tax Expenses	114	209	327	513	721
Profit After Tax	317	612	954	1,498	2,105
PAT Margin %	3.8%	5.1%	6.2%	7.4%	7.9%
Adjutsed EPS	4	8	12	19	27

Exhibit 2: Cash Flow Statement

Particulars	FY23	FY24	FY25E	FY26E	FY27E
Net cash generated from operating activities	540	(705)	1,170	1,590	2,296
Net cash (used in) investing activities	(1,418)	(4,277)	1,068	831	75
Net cash generated from / (used in) financing activities	722	4,790	720	(1,019)	(46)
Net (Decrease)/Increase in cash and cash equivalents	(157)	(193)	2,958	1,402	2,324
Cash & Cash Equivalents at the beginning of the year	769	612	417	3,375	4,777
Exchange Diff. on translation of foreign currency	0	(2)	0	0	0
Cash & Cash Equivalents at the end of the year	612	417	3,375	4,777	7,101

Exhibit 3: Key Ratios

Particulars	FY23	FY24	FY25E	FY26E	FY27E
Gross Profit Margin%	22%	23%	23%	24%	24%
EBITDA %	11%	9%	10%	12%	12%
PAT Margin %	4%	5%	6%	7%	8%
Return on Equity %	23%	11%	10%	14%	17%
Return on Capital %	15%	11%	11%	16%	21%
Adjutsed EPS (INR)	4.0	7.7	12.0	18.9	26.5

Source: Company, KRChoksey Research

Particulars	FY23	FY24	FY25E	FY26E	FY27E
Non-Current Assets					
(a) Property, plant and equipment	1,218	1,374	1,537	1,645	1,725
(b) Capital work in progress	13	10	10	10	10
(c) Right-of-use assets	345	494	490	486	482
(d) Goodwill	30	30	30	30	30
(e) Intangible assets	16	22	22	22	22
(f) Financial assets :	0	0	0	0	0
(i) Investments	895	662	662	662	662
Other Non-current assets	132	181	181	181	181
Total non-current assets	2,650	2,774	2,932	3,036	3,113
Current Assets					
Inventories	4,251	4,642	5,252	6,658	8,059
(b) Financial assets :	0	0	0	0	0
(i) Trade receivables	1,617	2,259	2,983	3,606	4,396
(ii) Cash and cash equivalents	773	417	3,375	4,777	7,101
(iii) Bank balances Other than (ii) above	903	4,949	3,456	2,200	1,700
(iv) Other financial assets	55	249	200	200	200
(c) Other current assets	798	743	771	757	764
Total current assets	8,397	13,259	16,037	18,199	22,221
Total Assets	11,047	16,033	18,969	21,235	25,333
EQUITY AND LIABILITIES					
Equity					
(a) Equity Share Capital	529	793	793	793	793
(b) Other Equity	1,450	8,297	9,251	10,749	12,854
TOTAL EQUITY	1,979	9,090	10,044	11,542	13,647
Liabilities					
Non-Current Liabilities					
(a) Financial Liabilities					
i. Borrowings	996	747	1,735	850	850
ii. Lease liabilities	363	515	540	580	620
iii. Other financial liabilities	166	181	181	181	181
(b) Other non-current liabilities	0	0	0	0	0
(c) Provisions	95	106	106	106	106
Total non-current liabilities	1,620	1,549	2,561	1,717	1,757
Current Liabilities					
(a) Financial liabilities :					
i. Borrowings	2,149	589	600	600	700
ii. Lease liabilities	53	70	70	75	80
iii. Trade payables	2,853	3,200	0	0	0
Total Trade Payable	2,853	3,200	4,158	5,766	7,614
iv. Other financial liabilities	76	217	217	217	217
(b) Other Current Liabilities	2,292	1,281	1,281	1,281	1,281
(c) Income tax liabilities (net)	22	34	34	34	34
(d) Provisions	3	3	3	3	3
Total current liabilities	7,449	5,394	6,363	7,975	9,929
Total Liabilities	9,068	6,943	8,925	9,692	11,686
TOTAL EQUITY AND LIABILITIES	11,047	16,033	18,969	21,235	25,333
Check	0	0	0	0	0
(d) Provisions	3	3	3	3	3
Total current liabilities	7,449	5,394	6,363	7,975	9,929
Total Liabilities	9,068	6,943	8,925	9,692	11,686
TOTAL EQUITY AND LIABILITIES	11,047	16,033	18,969	21,235	25,333

Cyient DLM Ltd.

Cyient DLM Ltd			
Date	CMP (INR)	TP (INR)	Recommendation
22-Oct-24	661	842	BUY
16-Oct-24	713	842	BUY

Rating Legend (Expected over a 12-month period)	
Our Rating	Upside
Buy	More than 15%
Accumulate	5% – 15%
Hold	0 – 5%
Reduce	-5% – 0
Sell	Less than – 5%

ANALYST CERTIFICATION:

I, Dipak Saha (MBA, Finance), Research Analyst, author and the name subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my views about the subject issuer(s) or securities. I also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Terms & Conditions and other disclosures:

KRChoksey Shares and Securities Pvt. Ltd (hereinafter referred to as KRCSSPL) is a registered member of National Stock Exchange of India Limited and Bombay Stock Exchange Limited. KRCSSPL is a registered entity with SEBI for Research Analyst in terms of SEBI (Research Analyst) Regulations, 2014 vide registration number INH000001295. It is also registered as a Depository Participant with CDSL, CDSL Registration No IN-DP-425-2019.

KRChoksey Shares & Securities Pvt Ltd. and DRChoksey Finserv Private Ltd. (Demerged entity from KRChoksey Shares & Securities Limited) are regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of Research Analysts including preparing and distribution of Research Reports. This research report is prepared and distributed by DRChoksey Finserv Private Ltd in the capacity of a Research Analyst as per Regulation 22(1) of SEBI (Research Analysts) Regulations 2014 having SEBI Registration No. INH00001246. It may be further notified that KRCSSPL carries on the activity of preparation as well as distribution of reports in the capacity of a Research Analyst as per Regulation 22(1) of SEBI (Research Analysts) Regulations 2014 having SEBI Registration No. INH000001295.

The information and opinions in this report are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of KRCSSPL. While we would endeavour to update the information herein on a reasonable basis, KRCSSPL is not under any obligation to update the information. Also, there may be regulatory, compliance or other reasons that may prevent KRCSSPL from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension follows applicable regulations and/or KRCSSPL policies, in circumstances where KRCSSPL might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. KRCSSPL will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. KRCSSPL accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Our employees in sales and marketing team, dealers and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed herein, in reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

We submit that no material disciplinary action has been taken on KRCSSPL and its associates (Group Companies) by any Regulatory Authority impacting Equity Research Analysis activities. KRCSSPL prohibits its associate, analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analyst covers.

KRCSSPL or its associates (Group Companies) collectively or its research analyst, or relatives do not hold any financial interest/beneficial ownership of more than 1% (at the end of the month immediately preceding the date of publication of the research report) in the company covered by Analyst, and has not been engaged in market making activity of the company covered by research analyst.

It is confirmed that, I, Dipak Saha Research Analyst of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific brokerage service transactions.

KRCSSPL or its Associates (Group Companies) have not managed or co-managed public offering of securities for the subject company in the past twelve months.

KRCSSPL or its associates (Group Companies) collectively or its research analyst, or relatives might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of brokerage services or specific transaction or for products and services other than brokerage services.

KRCSSPL or its associates (Group Companies) collectively or its research analyst, or relatives might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report other than investment banking or merchant banking or brokerage services from the subject company

KRCSSPL encourages the practice of giving independent opinion in research report preparation by the analyst and thus strives to minimize the conflict in preparation of research report. KRCSSPL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither KRCSSPL nor Research Analysts his associate or his relative, have any material conflict of interest at the time of publication of this report.

It is confirmed that, Dipak Saha, Research Analyst do not serve as an officer, director or employee of the companies mentioned in the report.

KRCSSPL or its associates (Group Companies) or its research analyst has been engaged in market making activity for the subject company.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other Jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject KRCSSPL and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform them of and to observe such restriction.

Please send your feedback to research.insti@krchoksey.com

In case of any grievances, please write to grievance@krchoksey.com

Visit us at www.krchoksey.com

KRChoksey Shares and Securities Pvt. Ltd.

CIN-U67120MH1997PTC108958

Registered Office: 1102, Stock Exchange Tower, Dalal Street, Fort, Mumbai – 400 001.

Phone: 91-22-6633 5000; Fax: 91-22-6633 8060

Corporate Office: 701-702, DLH Plaza, Opp Shoppers Stop, S V Road, Andheri (W), Mumbai 400 058

Phone: 91-22-66535000

Compliance Officer: Varsha Shinde

Email: varsha.shinde@krchoksey.com

RESEARCH ANALYST

Dipak Saha, research5@krchoksey.com, +91-22-6696 5408

KRChoksey Research

is also available on Bloomberg KRCS<GO>
Thomson Reuters, Factset and Capital IQ

Phone: +91-22-6696 5555, Fax: +91-22-6691 9576

www.krchoksey.com